JBIR-22, An Inhibitor for Protein−Protein Interaction of the Homodimer of Proteasome Assembly Factor 3

Izumikawa, Miho; Hashimoto, Junko; Hirokawa, Takatsugu; Sugimoto, Satoshi; Kato, Tomokazu; Takagi, Motoki; Shin‐ya, Kazuo

doi:10.1021/np900788e

Cited by 29 publications

(25 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another spongederived compound, JBIR-22, was later found to be an analogue of equisetin, an antibiotic compound produced by Fusarium spp. 256 . JBIR-22 was shown to be cytotoxic to HeLa cells 256 , but it was not otherwise characterized for biological activity.…”

Section: Protein Protein Interactions Protein Protein Interactions Amentioning

confidence: 99%

See 1 more Smart Citation

The re-emergence of natural products for drug discovery in the genomics era

Harvey

Edrada-Ebel

Quinn

2015

Nat Rev Drug Discov

2,112

1,410

View full text Add to dashboard Cite

Natural products have been a rich source of compounds for drug discovery. However, their use has diminished in the past two decades in part because of technical barriers to screening natural products in high-throughput assays against molecular targets. Here, we review advances in chemical techniques for the isolation and structural elucidation of natural products that have reduced these technological barriers. We also assess the use of genomic and metabolomic approaches to augment traditional methods of studying natural products, and highlight recent examples of natural products in antimicrobial drug discovery and as inhibitors of protein protein interactions. The growing appreciation of functional assays and phenotypic screens may further contribute to a revival of interest in natural products for drug discovery.

show abstract

Section: Protein Protein Interactions Protein Protein Interactions Amentioning

confidence: 99%

“…256 . JBIR-22 was shown to be cytotoxic to HeLa cells 256 , but it was not otherwise characterized for biological activity.…”

Section: Protein Protein Interactions Protein Protein Interactions Amentioning

confidence: 99%

The re-emergence of natural products for drug discovery in the genomics era

Harvey

Edrada-Ebel

Quinn

2015

Nat Rev Drug Discov

2,112

1,410

View full text Add to dashboard Cite

show abstract

“…JBIR-22, specifically inhibiting proteasome assembling chaperone homodimerization in vitro, could be a useful primary compound for developing anticancer drugs [58,59]. Due to its important bioactivity and unsolved stereochemical assignment, Healy et al developed an elegant synthetic route (Scheme 6) [27].…”

Section: C3-decalinoyl Ta (Jbir-22)mentioning

confidence: 99%

Recent Advances in the Total Synthesis of Tetramic Acid-Containing Natural Products

Bai

Lü

Wang

2016

Journal of Chemistry

View full text Add to dashboard Cite

With incredible bioactivities and fascinating structural complexities, tetramic acid- (TA-) containing natural products have attracted favorable attention among the organic chemistry community. Although the construction of the TA core is usually straightforward, the intricate C3-side chain sometimes asks for some deliberative strategy so as to fulfill an elegant total synthesis. This review mainly covers some exceptional synthetic examples for each type of natural product in recent years, showcasing the great achievements as well as unsettled obstacles in this area, in the hope of accelerating the synthetic and biological investigations for this unique type of natural product.

show abstract

“…24) and JBIR-22, which inhibits homodimer formation of proteasome assembly factor 3 (Ref. 25). Many of these natural products have intrinsic antitumour properties, although it is not clear whether this is solely attributable to their proteasome inhibitory capacities.…”

Section: Targeting Proteasome Subsets For Inhibition – Reducing Overamentioning

confidence: 99%

Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases

Edelmann

Nicholson

Kessler

2011

Expert Rev. Mol. Med.

View full text Add to dashboard Cite

Recent advances in the development and discovery of pharmacological interventions within the ubiquitin–proteasome system (UPS) have uncovered an enormous potential for possible novel treatments of neurodegenerative disease, cancer, immunological disorder and microbial infection. Interference with proteasome activity, although initially considered unlikely to be exploitable clinically, has already proved to be very effective against haematological malignancies, and more specific derivatives that target subsets of proteasomes are emerging. Recent small-molecule screens have revealed inhibitors against ubiquitin-conjugating and -deconjugating enzymes, many of which have been evaluated for their potential use as therapeutics, either as single agents or in synergy with other drugs. Here, we discuss recent advances in the characterisation of novel UPS modulators (in particular, inhibitors of ubiquitin-conjugating and -deconjugating enzymes) and how they pave the way towards new therapeutic approaches for the treatment of proteotoxic disease, cancer and microbial infection.

show abstract

JBIR-22, An Inhibitor for Protein−Protein Interaction of the Homodimer of Proteasome Assembly Factor 3

Cited by 29 publications

References 23 publications

The re-emergence of natural products for drug discovery in the genomics era

The re-emergence of natural products for drug discovery in the genomics era

Recent Advances in the Total Synthesis of Tetramic Acid-Containing Natural Products

Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases

Contact Info

Product

Resources

About